^
Association details:
| Biomarker: | EGFR C797S |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | TRX-221 (EGFR inhibitor, EGFR C797S inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2357P - TRX-221, a 4th generation, mutant-selective, and CNS-active EGFR inhibitor with robust antitumor activity in osimertinib-resistant tumor models harboring C797S mutation
Published date:
10/16/2023
Excerpt:
In osimertinib-resistant xenograft tumor models harboring EGFR C797S mutant cells, TRX-221 induced significant tumor regression without body weight loss...TRX-221 demonstrates strong antitumor efficacy in osimertinib-resistant tumor models, and thus has potential to treat patients who have developed resistance to 3rd generation EGFR TKI treatment.
